Table 4 Prognostic factors of overall survival

Age (≥60 vs. < 60 yrs)

1.42(0.77 ~ 2.60)

0.256

Sex (male vs. female)

0.05(0.01 ~ 18.45)

0.314

Charlson comorbidity index (≥1 vs. 0)

1.46(0.78 ~ 2.71)

0.232

Performance status (1 vs. 0)

1.12(0.63 ~ 2.01)

0.691

Tumor location (U/M third vs. L third/EGJ)

1.12(0.61 ~ 2.05)

0.717

Tumor length

1.01(0.86 ~ 1.18)

0.882

Neoadjuvant therapy (yes vs. no)

0.93(0.50 ~ 1.73)

0.820

(y)p T stage (T3 vs. T0–2)

2.64(1.46 ~ 4.75)

0.001

3.17(1.57 ~ 6.37)

0.001

(y)p N stage (N+ vs. N0)

1.59(0.89 ~ 2.85)

0.116

Differentiation (poorly vs. well + moderately)

2.07(0.86 ~ 4.97)

0.105

LVI (+ vs. -)

1.61(0.90 ~ 2.89)

0.107

PNI (+ vs. -)

1.33(0.59 ~ 3.01)

0.486

TRG (0 vs. 1–3)

0.55(0.23 ~ 1.31)

0.176

CRM (involved or close vs. uninvolved)

1.92(0.91 ~ 4.03)

0.085

 Disease free interval (>  12 vs. ≤ 12 months)

0.39(0.22 ~ 0.71)

0.002

0.54(0.28 ~ 1.03)

0.062

Recurrence pattern

 Distant vs. loco-regional

0.87(0.48 ~ 1.56)

0.638

 Lung (with vs. without)

0.57(0.30 ~ 1.08)

0.086

 Liver (with vs. without)

1.03(0.32 ~ 3.35)

0.956

 Bone (with vs. without)

3.19(0.76 ~ 13.46)

0.114

 Brain (with vs. without)

3.83(1.13 ~ 12.94)

0.031

8.21(2.19 ~ 30.78)

0.002

 Pleural/Chest wall (with vs. without)

1.17(0.42 ~ 3.30)

0.760

 Cervical lymph node (with vs. without)

1.01(0.47 ~ 2.17)

0.972

 Mediastinum (with vs. without)

2.37(1.15 ~ 4.85)

0.019

4.21(1.88 ~ 9.43)

0.001

 Anastomosis (with vs. without)

0.26(0.60 ~ 1.15)

0.077

 Operation for recurrence (yes vs. no)

0.62(0.34 ~ 1.12)

0.114